152 related articles for article (PubMed ID: 11131921)
1. Early detection of relapse and evaluation of treatment for mixed chimerism using fluorescence in situ hybridization following allogeneic hematopoietic cell transplant for hematological malignancies.
Tamura S; Saheki K; Takatsuka H; Wada H; Fujimori Y; Okamoto T; Takemoto Y; Hashimoto-Tamaoki T; Furuyama J; Kakishita E
Ann Hematol; 2000 Nov; 79(11):622-6. PubMed ID: 11131921
[TBL] [Abstract][Full Text] [Related]
2. [Monitoring of bcr/abl fusion gene by interphase-dual-color and dual-fusion fluorescence in situ hybridization in CML after allo-HSCT].
Qian SX; Li JY; Zhang R; Hong M; Qiu HR; Li L; Xu W; Sheng RL; Wu HX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Jun; 14(3):577-81. PubMed ID: 16800946
[TBL] [Abstract][Full Text] [Related]
3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
4. [Study of the time course of mixed chimerism by fluorescent in situ hybridization in patients with chronic myeloid leukemia after allogenic transplantation of bone marrow].
Vinogradova OA; Savchenko VG; Neverova AL; Diachenko LV; Domracheva EV; Liubimova LS; Mendeleeva LP
Ter Arkh; 2001; 73(7):26-34. PubMed ID: 11523405
[TBL] [Abstract][Full Text] [Related]
5. Donor lymphocyte infusion followed by interferon-alpha plus low dose cyclosporine A for modulation of donor CD3 cells activity with monitoring of minimal residual disease and cellular chimerism in a patient with first hematologic relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation.
Leda M; Ladon D; Pieczonka A; Boruczkowski D; Jólkowska J; Witt M; Wachowiak J
Leuk Res; 2001 Apr; 25(4):353-7. PubMed ID: 11248334
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
7. FISH analysis of native smears from bone marrow and blood for the monitoring of chimerism and clonal markers after stem cell transplantation in children.
Fuehrer M; Gerusel-Bleck M; Konstantopoulos N; Bender-Goetze C; Walther JU
Int J Mol Med; 2005 Feb; 15(2):291-7. PubMed ID: 15647846
[TBL] [Abstract][Full Text] [Related]
8. Quantitative analysis of chimerism after allogeneic stem cell transplantation by real-time polymerase chain reaction with single nucleotide polymorphisms, standard tandem repeats, and Y-chromosome-specific sequences.
Koldehoff M; Steckel NK; Hlinka M; Beelen DW; Elmaagacli AH
Am J Hematol; 2006 Oct; 81(10):735-46. PubMed ID: 16838323
[TBL] [Abstract][Full Text] [Related]
9. [The clinical significance of interphase fluorescence in situ hybridization monitoring chimeric status after sex-mismatched allogeneic hematopoietic stem cell transplantation for leukemia].
Liu Q; Song L; Zhang Y; Wei Y; Xu D; Sun J; Liu X; Xu B; Meng F; Zhou S
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2005 Apr; 22(2):212-5. PubMed ID: 15793790
[TBL] [Abstract][Full Text] [Related]
10. [Application of sequential and quantitative monitoring of chimerism in allogeneic hematopoietic stem cell transplantation].
Tang XW; Wu DP; Zhu ZL; Wang W; Sun AN; Qiu HY; Fu ZZ; Chang WR; Ruan CG
Zhonghua Xue Ye Xue Za Zhi; 2004 Feb; 25(2):78-81. PubMed ID: 14990044
[TBL] [Abstract][Full Text] [Related]
11. [Dynamic detection of chimerism and fusion gene in chronic myeloid leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation].
Sun JF; Zhao DD; Han XP; Jin HS; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):833-7. PubMed ID: 18718071
[TBL] [Abstract][Full Text] [Related]
12. Molecular studies of chimerism and minimal residual disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation.
Elmaagacli AH; Beelen DW; Becks HW; Mobascher A; Stockova J; Trzensky S; Opalka B; Schaefer UW
Bone Marrow Transplant; 1996 Aug; 18(2):397-403. PubMed ID: 8864452
[TBL] [Abstract][Full Text] [Related]
13. Real-time quantitative Y chromosome-specific PCR (QYCS-PCR) for monitoring hematopoietic chimerism after sex-mismatched allogeneic stem cell transplantation.
Fehse B; Chukhlovin A; Kühlcke K; Marinetz O; Vorwig O; Renges H; Krüger W; Zabelina T; Dudina O; Finckenstein FG; Kröger N; Kabisch H; Hochhaus A; Zander AR
J Hematother Stem Cell Res; 2001 Jun; 10(3):419-25. PubMed ID: 11454317
[TBL] [Abstract][Full Text] [Related]
14. Detection of relapse by sequential monitoring of chimerism in circulating CD34+ cells.
Thiede Ch; Lutterbeck K; Oelschlägel U; Kiehl M; Steudel Ch; Platzbecker U; Brendel C; Fauser AA; Neubauer A; Ehninger G; Bornhäuser M
Ann Hematol; 2002; 81 Suppl 2():S27-8. PubMed ID: 12611065
[TBL] [Abstract][Full Text] [Related]
15. Importance of mixed chimerism to predict relapse in persistently BCR/ABL positive long survivors after allogeneic bone marrow transplantation for chronic myeloid leukemia.
Román J; Martín C; Torres A; García A; Andrés P; García MJ; Baiget M
Leuk Lymphoma; 1998 Feb; 28(5-6):541-50. PubMed ID: 9613984
[TBL] [Abstract][Full Text] [Related]
16. Mixed chimerism of bone marrow vessels (endothelial cells, myofibroblasts) following allogeneic transplantation for chronic myelogenous leukemia.
Kvasnicka HM; Wickenhauser C; Thiele J; Varus E; Hamm K; Beelen DW; Schaefer UW
Leuk Lymphoma; 2003 Feb; 44(2):321-8. PubMed ID: 12688352
[TBL] [Abstract][Full Text] [Related]
17. [Preventative and therapeutic relapse strategies after allogeneic hematopoietic stem cell transplantation: Guidelines from the Francophone society of bone marrow transplantation and cellular therapy (SFGM-TC)].
Yafour N; Beckerich F; Bulabois CE; Chevallier P; Daguindau É; Dumesnil C; Guillaume T; Huynh A; Levrat SM; Menard AL; Michallet M; Pautas C; Poiré X; Ravinet A; Yakoub-Agha I; Bazarbachi A
Bull Cancer; 2017 Dec; 104(12S):S84-S98. PubMed ID: 29179894
[TBL] [Abstract][Full Text] [Related]
18. Need for an accurate molecular diagnosis to assess the donor origin of leukemia relapse after allogeneic stem cell transplantation.
Spinelli O; Giussani U; Borleri G; Lazzari M; Michelato A; Dotti G; Barbui T; Rambaldi A
Haematologica; 2000 Nov; 85(11):1153-7. PubMed ID: 11064467
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning.
Lange T; Hubmann M; Burkhardt R; Franke GN; Cross M; Scholz M; Leiblein S; Al-Ali HK; Edelmann J; Thiery J; Niederwieser D
Leukemia; 2011 Mar; 25(3):498-505. PubMed ID: 21135860
[TBL] [Abstract][Full Text] [Related]
20. Fluorescent in situ hybridization on flow-sorted cells as a tool for evaluating minimal residual disease or chimerism after allogenic bone marrow transplantation.
Cotteret S; Belloc F; Boiron JM; Bilhou-Nabera C; Dumain P; Boyer C; Lacombe F; Reiffers J; Bernard P
Cytometry; 1998 Oct; 34(5):216-22. PubMed ID: 9822307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
